Muscarinic receptor ligands and their therapeutic potential

Current Opinion in Chemical Biology

Volumn 3, Issue 4, 1999, Pages 426-432

  Eglen, Richard M ^a   Choppin, Agnes ^a   Dillon, Michael P ^a   Hegde, Sharath ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DICHLORO 6,7,8,9,10,12 HEXAHYDROAZEPINO[2,1 B]QUINAZOLINE; 2,8 DIMETHYL 1,3 DIOXA 8 AZASPIRO[4.5]DECANE; 2,8 DIMETHYL 3 METHYLENE 1 OXA 8 AZASPIRO[4.5]DECANE; CEVIMELINE; DARIFENACIN; ITAMELINE; LIGAND; LY 287041; MILAMELINE; MUSCARINIC AGENT; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NERISPIRDINE; OXYBUTYNIN; QUINUCLIDIN 4 YLBIPHENYL 2 YLCARBAMIC ACID; RECEPTOR SUBTYPE; SABCOMELINE; SNAKE VENOM; SOLIFENACIN; SR 462559; TALSACLIDINE; TEMIVERINE; TIOTROPIUM; TOLTERODINE; UNCLASSIFIED DRUG; VAMICAMIDE; XANOMELINE;

ALZHEIMER DISEASE; ANALGESIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; HUMAN; LIGAND BINDING; MOLECULAR RECOGNITION; PAIN; PHYSIOLOGY; RECEPTOR BINDING; REVIEW; URINE INCONTINENCE;

SERPENTES;

EID: 0033179509     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(99)80063-5     Document Type: Article

References (43)

1. Eglen RM, Watson N: Selective muscarinic agonists and antagonists. Pharmacol Toxicol 1996, 78:59-68.
2. Eglen RM, Hegde SS: Muscarinic receptor subtypes: Pharmacology and therapeutic potential. Drugs 1997, 10:462-469.
3. Caulfield MP, Birdsall NJM: International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Revs 1998, 50:279-290. Detailed review of muscarinic receptor pharmacology, molecular biology and biochemistry
4. Avery EE, Baker LD, Asthana S: Potential role of muscarinic agonists in Alzheimer's disease. Drugs Aging 1997, 11:450-459.
5. Fisher A: Muscarinic agonists for the treatment of Alzheimer's disease: Progress and perspectives. Exp Op Invest Drugs 1997, 6:1395-1411.
6. 2 receptor selective antagonist. Life Sci 1999, 64:535-539.
7. Nitsch RN, Slack BE, Wurtmann RJ, Growdon JH: Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992, 258:304-307.
8. Buxbaum JD, Oishi M, Chen HI et al.: Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzhheimer β/A4 amyloid protein precursor. Proc Natl Acad Sci USA 1998, 89:10075-10078.
9. 1 agonists in Alzheimer's disease.
10. Sramek JJ, Hurley DJ, Wardle TS, Satterwhite JH, Hourani J, Dies F, Cutler NR: The safety and tolerability of xanomeline tartrate in patients with Alzheimer's disease. J Clin Pharmacol 1995, 35:800-806.
11. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP et al.: Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease. Arch Neurol 1997, 54:465-473.
12. Kumar R, Cedar E, Clark MSG, Loudon JM, McCafferty JPC: Muscarinic partial agonists in the symptomatic treatment of Alzheimer's disease. In Alzheimer's Disease: From Molecular Biology to Therapy. Edited by Becker R, Giacobini E. Boston: Birkauser; 1996:299-303.
13. 4 subtype. J Pharm Exp Ther 1999, 288:1143-1150.
14. Petry NM, Bickel WK, Huddleston J, Tzanis E, Badger GJ: A comparison of subjective psychomotor and physiological effects of a novel muscarinic analgesic, LY 297802 tartrate and oral morphine in occasional drug users. Drug Alcohol Depend 1998, 50:129-136.
15. 2 receptor expression.
16. Sauerberg P, Jeppesen L, Olesen PH, Rasmussen T, Swedberg MDB, Sheardown M, Fink-Jensen A, Thomsen C, Thogersen H, Rimvall K et al.: Muscarinic agonists with antipsychotic-like activity: Structure activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity. J Med Chem 1998, 41:4378-4384.
17. Resnick NM, Ouslander JG: National Institute of Health consensus development conference on urinary incontinence. J Am Geriatric Soc 1990, 38:263-286.
18. Cukier JM, Cortina-Borja M, Brading AF: A case-control study to examine any association between idiopathic detrusor instability and gastrointestinal tract disorder, and between irritable syndrome and urinary tract disorder. Br J Urol 1997, 79:865-878.
19. Baxandale A, Bountra C, Clayton N, Humphrey PPA, KolowsKi K, Mangel A, O'Sullivan M: Irritable bowel syndrome as visceral hyperalgesia: Implications for therapy? Curr Opin CPNS Drugs 1999, 1:86-97.
20. Manfreda J, Mao Y, Litven W: Morbidity and mortality from chronic obstructive pulmonary disease. Am Rev Respir Dis 1992, 140:S19-S26.
21. Resnick NM: Urinary incontinence. Lancet 1995, 346:94-99.
22. Swami SK, Abrams P: Urge incontinence. Urol Clin North Am 1996, 23:417-425.
23. Yarker YE, Goa KL, Fitton A: Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995, 6:243-262.
24. Chapman KR: Therapeutic approaches to chronic obstructive pulmonary disease: An emerging consensus. Am J Med 1996, 100(suppl 1A):5.
25. Drossman DA, Thompson WG: The irritable bowel syndrome: Review and a graduated multicomponent treatment approach. Ann Int Med 1992, 116:1009-1016.
26. Eglen RM, Hegde SS, Watson N: Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev 1996, 48:531-565.
27. 2 antagonists for clinical use. Life Sci 1997, 60:1053-1060.
28. Homma Y, Asoi Y, Kawabe K, Kumamoto Y, Tsuchida M, Nishizawa O, Shimazaki J, Yasuda K, Kurita T, Kumazawa J et al.: Randomized double-blind study to compare clinical efficacy of temiverine and propiverine for unstable bladder and detrusor hyperreflexia. Neurourol Urodyn 1997, 16:345-346.
29. Kobayashi S, Iked K, Hirano H, Kitagawa H, Takeuchi M, Naito R, Yamada T, Isomura Y, Takemoto T: Effects of antimuscarinics on urinary bladder and salivary gland. Nippon Yakurigashi Zasshi 1996, 71 (suppl 1):328P.
30. Hills CJ, Winter SA, Balfour JA: Tolterodine. Drugs 1998, 55:813-820. Overview of the preclinical and clinical pharmacology of tolterodine.
31. Gillberg PG, Sundquist S, Nilvebrandt L: Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype selective muscarinic receptor antagonists. Eur J Pharmacol 1998, 349:285-292.
32. Abrams P, Freeman R, Anderstrom C, Mattiasson A: Tolterodine, a new antimuscarinic agent; as effective but better tolerated than oxybutynin in patients with overactive bladder. Br J Urol 1998, 81:801-810.
33. Rentzhog L, Stanton SL, Cardozo L, Nelson E, Fall M, Abrams P: Efficacy and safety of tolterodine in patients with detrusor instability: A dose ranging study. Br J Urol 1998, 81:42-48.
34. Nilvebrant L, Hallen B, Larsson G: Tolterodine - A new bladder selective muscarinic receptor antagonist: Preclinical pharmacological and clinical data. Life Sci 1997, 60:1129-1136.
35. 3 selective muscarinic antagonist, reduces colonie motor activity in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1997, 11:561-568.
36. Mitch CH, Brown TJ, Bymaster FP, Calligaro DO, Dieckman D, Merrit L, Peters SC, Quimby SJ, Shannon HE, Shipley LA et al.: Muscarinic analgesics with potent and selective effects on the gastrointestinal tract: Potential application for the treatment of irritable bowel syndrome. J Med Chem 1997, 40:538-546.
37. Osayu H, Yamamoto T, Sato N, Sawada T, Ozaki R, Mukai T, Ozaki T, Nishii M, Sato H, Fujiwara T et al.: Urinary bladder selective action of the new antimuscarinic compound vamicamide. Arzneimittelforschung 1994, 44:1242-1249.
38. Naito R, Takeuchi M, Mosihira K, Hayakawa M, Ikeda K, Shibanuma T, Isomura Y: N-biphenylcarbamate derivatives: A novel class of selective muscarinic antagonists [abstract]. Proceedings of the 14th International Symposium of Medicinal Chemistry. 1996:2.28.
39. Gupta SK, Sathyan G: Pharmacokinetics of an oral once a day controlled release oxybutynin formulation compared with immediate release oxybutynin. J Clin Pharmacol 1999, 39:289-296.
40. Maesen FPV, Smeets JJ, Sledsens TJH, Wald FDM, Cornel-Issen PJG: Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: A pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 1995, 8:1506-1513.
41. Disse B, Speck GA, Rominger KL, Witek TJ, Hammer R: Tiotropium (Spirva): Mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999, 64:457-464.
42. Plotnick LH, Ducharme FM: Should inhaled anticholinergics be added to β2 agonists for treating acute childhood and adolescent asthma? Br Med J 1998, 317:971-977.
43. Eglen RM, Hegde SS: Selective modulation of muscarinic receptor subtypes: Therapeutic potential. Emerging Drugs 1998, 3:67-79.